Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review-Reference-Cited by-同舟云学术

Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review

Published:2019-09-20 Issue:22 Volume:26 Page:4241-4252
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

Fogagnolo Paolo¹,Torregrossa Giulia¹,Tranchina Laura¹,Ferreras Antonio²,De Cillá Stefano³,Labbé Antoine⁴,Figus Michele⁵,Ottobelli Laura¹,Rossetti Luca¹

Affiliation:

1. Eye Clinic, San Paolo Hospital, University of Milan, Milan, Italy

2. Department of Ophthalmology, Miguel Servet University Hospital, University of Zaragoza, Zaragoza, Spain

3. Unit of Ophthalmology, Ospedale Maggiore della Carita, Novara, Italy

4. Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, Vision Institute, Versailles Saint-Quentin en Yvelines University, 75012 Paris, France

5. Ophthalmology, Department of Neurosciences, University of Pisa, Pisa, Italy

Abstract

Glaucoma is the second leading cause of blindness in the world, affecting more than 60 million people globally. In order to reduce the progression of the disease, both medical and surgical treatments are used. Frequent side effects of both treatments include a range of modifications of the ocular surface grouped as the Ocular Surface Disease (OSD), which include Dry Eye Disease (DED). DED and other OSD negatively impact on the success of anti-glaucoma treatments and reduce the adherence to medical therapies. Tear film osmolarity (TFO) is a relatively novel test which has become a hallmark of DED. The aim of this paper was to review the association between OSD, DED and glaucoma in view of published TFO data, and to discuss future fields of research and treatments on the topic of glaucoma iatrogenic damage.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Reference88 articles.

1. Quigley H.A.; Broman A.T.; The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006,90(3),262-267

2. Fogagnolo P.; Rossetti L.; Medical treatment of glaucoma: present and future. Expert Opin Investig Drugs 2011,20(7),947-959

3. Erb C.; Gast U.; Schremmer D.; German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefe’s archive for clinical and experimental ophthalmology =. Albrecht Von Graefes Arch Klin Exp Ophthalmol 2008,246(11),1593-1601

4. Leung E.W.; Medeiros F.A.; Weinreb R.N.; Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008,17(5),350-355

5. Garcia-Feijoo J.; Sampaolesi J.R.; A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol 2012,6,441-446

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of therapeutic efficacy of Emustil drops for ocular discomfort and tear film osmolarity using different treatment management modes under dry environmental conditions;BMC Ophthalmology;2024-03-25

2. FAST® questionnaire for identifying glaucoma patients at risk for ocular surface disease;European Journal of Ophthalmology;2024-02-22

3. Effectiveness of a New Active Tear Substitute Containing 0.2% Hyaluronic Acid and 0.001% Hydrocortisone on Signs and Symptoms of Dry Eye Disease by Means of Low- and High-Tech Assessments;Ophthalmology and Therapy;2023-11-10

4. Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications;Journal of Ocular Pharmacology and Therapeutics;2023-07-01

5. Factors influencing the effectiveness of trabeculectomy: following materials of the City Multidisciplinary Hospital No. 2;Ophthalmology Reports;2023-02-20